Strategy Asset Managers’s Vertex Pharmaceuticals VRTX Stock Holding History

Strategy Asset Managers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.62M	Buy	3,097 +37	+1%	+$18.9K	0.25%	74
2026 Q2	$1.52M	Sell	3,060 -104	-3%	-$46.1K	0.23%	83
2026 Q1	$1.41M	Sell	3,164 -27	-0.8%	-$12.6K	0.23%	76
2025 Q4	$1.45M	Buy	3,191 +198	+7%	+$85.3K	0.24%	71
2025 Q3	$1.17M	Buy	2,993 +51	+2%	+$21.3K	0.21%	79
2025 Q2	$1.31M	Buy	2,942 +99	+3%	+$45.6K	0.24%	73
2025 Q1	$1.38M	Buy	2,843 +229	+9%	+$107K	0.28%	69
2024 Q4	$1.05M	Sell	2,614 -95	-4%	-$44K	0.2%	86
2024 Q3	$1.26M	Sell	2,709 -1,805	-40%	-$867K	0.24%	74
2024 Q2	$1.59M	Buy	4,514 +2,116	+88%	+$918K	0.35%	58
2024 Q1	$1M	Sell	2,398 -1,490	-38%	-$630K	0.21%	77
2023 Q4	$1.58M	Sell	3,888 -188	-5%	-$69.4K	0.38%	54
2023 Q3	$1.42M	Sell	4,076 -438	-10%	-$153K	0.37%	55
2023 Q2	$1.59M	Buy	4,514 +264	+6%	+$89K	0.35%	58
2023 Q1	$1.34M	Buy	4,250 +2,488	+141%	+$746K	0.33%	62
2022 Q4	$509K	Hold	1,762	–	–	0.13%	131
2022 Q3	$510K	Buy	1,762 +435	+33%	+$125K	0.14%	135
2022 Q2	$374K	Buy	1,327 +139	+12%	+$37.2K	0.12%	124
2022 Q1	$310K	Buy	+1,188	New	+$282K	0.07%	198

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Strategy Asset Managers's VRTX Position: Q3 2026 in Review

Strategy Asset Managers increased its Vertex Pharmaceuticals (VRTX) stake by 1.2% in Q3 2026, buying an estimated $18.9K and bringing the position to 3,097 shares worth $1.62M. The position accounts for 0.25% of the portfolio, ranked #74.

Strategy Asset Managers first reported a position in VRTX in Q1 2022 and has held it in 19 quarters since. 291 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Strategy Asset Managers held 3,097 shares of Vertex Pharmaceuticals worth $1.62M as of Q3 2026.
Strategy Asset Managers bought 37 Vertex Pharmaceuticals shares in Q3 2026, an estimated $18.9K.
Vertex Pharmaceuticals made up 0.25% of Strategy Asset Managers's portfolio in Q3 2026, its #74 holding.
Strategy Asset Managers first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 19 quarters since.
291 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Strategy Asset Managers's 13F filing for Q3 2026, filed 14 Oct 2026.